Show simple item record

dc.creatorGonzález Ramírez, Esteban
dc.creatorAlfaro Cartín, Silvia
dc.creatorRamos Esquivel, Allan Eduardo
dc.creatorLandaverde Recinos, Denis
dc.date.accessioned2018-06-08T15:09:56Z
dc.date.available2018-06-08T15:09:56Z
dc.date.issued2016-10-21
dc.identifier.citationhttp://jcmtjournal.com/article/view/1503/1195es_ES
dc.identifier.issn2454-2857
dc.identifier.urihttp://hdl.handle.net/10669/74873
dc.description.abstractAim: Tyrosine kinase inhibitors are part of the armamentarium to treat metastatic renal cell carcinomas (mRCC). Costa Rica has approved sunitinib in the first line setting. The authors conducted a retrospective study to address the effectiveness and safety profile of sunitinib in our population in terms of overall survival (OS) and progression free survival (PFS). Methods: The authors analyzed all patients who were treated with sunitinib diagnosed with mRCC in the three National Hospitals (Hospital Mexico, Hospital San Juan de Dios, and Hospital Calderon Guardia) from February 2007 to June 2015. Demographics, safety profile, and efficacy (OS and PFS) were obtained from medical records. OS and PFS were calculated using the Kaplan Meier method and a Cox Proportional Model Analysis was used when OS and PFS were compared in subset of patients. Results: Seventy-seven patients were included; mean age was 58.9 years. Fifty-four patients were male (70.1%). The most common histologic type was clear cell carcinoma (87%), followed by papillary (9.1%) and chromophobe (2.0%) types. Median OS was 21.0 months [95% confidence interval (CI): 13.42-28.58]. Median PFS was 13.7 months (95% CI: 11.24-16.16). Patients aged 65 years or older experienced worse PFS and OS than younger patients (median PFS: 8.2 vs. 17.6 months; P = 0.011) (median OS: 19.0 vs. 29.0 months; P = 0.022). Sunitinib was well tolerated and no serious side effects were reported. Conclusion: This is the first study in Central America showing that sunitinib, first line, in mRCC is as effective as reported in pivotal clinical trials and expanded use studies in terms of PFS and OS.es_ES
dc.language.isoen_USes_ES
dc.rightsCC0 1.0 Universal*
dc.rights.urihttp://creativecommons.org/publicdomain/zero/1.0/*
dc.sourceJournal of Cancer Metastasis and Treatment, Vol. 2(10), pp 396-401es_ES
dc.subject
Sunitinibes_ES
dc.subject
renal cell carcinomaes_ES
dc.subjecteffectivenesses_ES
dc.subjectLatin Americaes_ES
dc.subjectCosta Ricaes_ES
dc.subject616.994 728 Cáncereses_ES
dc.titleSunitinib effectiveness and safety as first line treatment in metastatic renal cell carcinoma, in the Costa Rican populationes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.typeArtículo científicoes_ES
dc.identifier.doi10.20517/2394-4722.2016.27
dc.description.procedenceUCR::Vicerrectoría de Docencia::Salud::Facultad de Medicina::Escuela de Medicinaes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

CC0 1.0 Universal
Except where otherwise noted, this item's license is described as CC0 1.0 Universal